Hallucinogen Addiction

What Are Hallucinogens?

Hallucinogens are drugs that change perception, mood, thinking, and a person’s sense of reality. They include psychedelics and dissociative drugs, which can make someone feel disconnected from their body or surroundings. Understanding the differences matters because an experience can feel pleasant or meaningful while still impairing judgment, and effects can become frightening or medically dangerous.^[1]

How Hallucinogens Affect Everyday Life

Hallucinogens can change how colors, sounds, time, movement, and the self are perceived. Emotions may shift quickly from enjoyment or connection to fear, confusion, or panic. Thinking and communication can become disorganized, and sensations may seem real even when they do not reflect what is happening around the person.^[2][1]

These changes matter beyond the experience itself. Impaired perception and judgment can make driving, navigating traffic, swimming, using equipment, or recognizing danger unsafe. Dissociative drugs can also impair memory and movement or cause numbness. Someone may feel capable of an activity while their ability to perform it safely is reduced.^[2][1]

A person who feels unusually connected to their surroundings might believe they can cross a busy road safely, while misjudging traffic or time. Hallucinogen use has been linked to dangerous behavior and injuries.^[1]

A survey of almost 2,000 people who had a challenging psilocybin experience outside medical care found that 11% reported putting themselves or someone else at risk of harm.^[1] That figure does not describe all psilocybin users: the survey specifically involved people who had already described a difficult experience.^[1]

Why Mindset and Surroundings Affect Hallucinogen Experiences

“Set and setting” means a person’s mindset and the environment in which use occurs. Mood, expectations, personality, the people present, and physical surroundings can influence an experience. A previous pleasant experience does not make the next response predictable.^[1]

An ethical analysis in Transcultural Psychiatry argues that psychedelics may increase suggestibility, the tendency to be influenced by other people, expectations, rituals, and explanations. The authors propose that this could support therapeutic processes but also encourage harmful interpretations or behavior. This is an argument about how context may work, not proof of a treatment benefit.^[6]

Recognizing When Hallucinogen Use Is Becoming a Problem

A substance use disorder is a pattern of use that causes significant impairment or distress. Signs include craving, hazardous use, missed responsibilities, substantial time obtaining or recovering from a drug, relationship problems, or continued use despite health consequences. You do not have to wait for daily use, withdrawal, or a crisis to ask for support.^[7]

Addiction and withdrawal risks differ by drug. Limited research suggests classic psychedelics such as LSD and psilocybin do not typically lead to addiction, although tolerance (needing more to obtain similar effects) can develop quickly. Physical withdrawal symptoms are typically not experienced when chronic classic-hallucinogen use stops. Nonmedical ketamine can produce cravings and withdrawal symptoms, and MDMA also has potential for problematic use.^[1][2][4]

Withdrawal is not required for the diagnosis of “other hallucinogen use disorder,” and phencyclidine (PCP) use disorder has a separate diagnostic category. In the 2025 National Survey on Drug Use and Health, an estimated 495,000 people ages 12 or older met criteria for hallucinogen use disorder during the previous year, about 0.2% of that population, not 0.2% of people who used hallucinogens.^[3][1][8]

How Major Hallucinogens Differ

The main distinctions involve how the drugs act in the brain and what people experience. Classic psychedelics mainly interact with receptors for serotonin, a chemical messenger. Receptors are structures through which cells respond to chemical signals. Dissociatives such as ketamine and phencyclidine block certain receptors involved in glutamate signaling, which contributes to learning, memory, emotion, and pain perception.^[1][2]

Another group includes drugs called empathogens or entactogens, meaning substances that can heighten feelings of empathy and emotional connection. The drug 3,4-methylenedioxymethamphetamine (MDMA), also called ecstasy or molly, has these effects as well as stimulant-like effects, such as increased energy and alertness. Experts do not classify every substance in exactly the same way.^[3][4][9]

Hallucinogen Forms and How Long Their Effects Last

The National Institute on Drug Abuse (NIDA) describes ingested classic hallucinogen effects as generally beginning within 20–90 minutes and lasting as long as 12 hours. It describes dissociative effects after ingestion as typically beginning within minutes and lasting several hours, with some people reporting effects for days.^[2]

These are broad group descriptions, not precise estimates for every drug or route.^[2]

Psilocybin Effects and Timing

Psilocybin is a classic psychedelic that can alter perception, mood, and sense of self. It occurs in certain mushrooms, commonly called “shrooms” or “magic mushrooms.”^[1]

In a study of healthy participants given measured oral psilocybin, average subjective effects lasted 5.5–6.4 hours across the studied doses.^[10] These research averages do not predict the duration of an unknown mushroom product or an individual’s symptoms.^[10]

LSD Effects and Timing

LSD (lysergic acid diethylamide) is a classic psychedelic with marked mood and perception changes. It is most commonly described as drug-soaked blotter paper, but also comes as liquid, tablets, or thin gelatin squares.^[2]

NIDA’s broad description of ingested classic hallucinogens (20–90 minutes to onset and up to 12 hours of effects) provides context, not a precise LSD-specific schedule.^[2]

DMT Effects and Timing

DMT (N,N-dimethyltryptamine) is a psychedelic compound found in some plants. A toxicology review describes common routes as oral use, snorting, intravenous injection, and smoking. It also discusses inhaled vapor.^[1][11]

With inhaled vapor or intravenous injection, full effects were reported within 2 minutes and subjective effects resolved within 20–30 minutes. These estimates do not apply to every route. The review reports 30–60 minutes of effects after injection into muscle.^[11]

Ketamine Effects and Timing

Ketamine is a dissociative that can cause detachment. Moderate to high doses can cause sedation, immobility, and memory loss. NIDA’s report describes nonmedical use of ketamine powder by snorting and illicit pill forms.^[2]

Ketamine is manufactured as an injectable liquid and used clinically as an anesthetic, a medicine to prevent pain and awareness during procedures. Nasal and sublingual, or under-the-tongue, formulations have also been studied or developed.^[2][12]

NIDA’s broad dissociative-group description concerns effects after ingestion: onset within minutes and effects lasting several hours, sometimes longer. It is not a precise ketamine-specific schedule or an estimate for every route.^[2]

Phencyclidine (PCP) Effects and Timing

PCP is a dissociative that can impair movement and cause anxiety or psychosis, hallucinations, fixed false beliefs, or difficulty recognizing reality.^[1] It is usually described as liquid or powder, but also comes in tablets or capsules. It may be smoked, swallowed, snorted, or injected.^[2]

For PCP, the general dissociative timeline is a broad reference, not a drug- or route-specific prediction. Psychiatric symptoms can persist beyond intoxication.^[2][1]

MDMA Effects and Timing

MDMA may increase energy, warmth, openness, and sensory sensitivity. It is sold illicitly in tablets, capsules, powder, or liquid. “Molly” may refer to powder or crystals.^[4][3]

NIDA describes effects beginning within about 45 minutes after a single dose and lasting an average of about 3 hours. A later comedown is a separate after-effect.^[4][3]

Other substances also produce dissociative or psychedelic effects. Dextromethorphan (DXM), an ingredient in some nonprescription cough medicines, can produce dissociative effects when misused. These products may also contain antihistamines or decongestants. Salvia works differently from classic psychedelics and from ketamine or PCP. A shared label does not imply a shared mechanism or safety profile.^[2][1]

New psychoactive substances are newer mind-altering compounds or diverted medicines sold as substitutes for controlled drugs. Their composition, potency, duration, and risks may be poorly understood. A product’s appearance or name does not establish its contents, and being marketed as “legal” does not establish safety.^[13]

Timing estimates are not recovery deadlines. Do not use them to decide that someone must be safe to drive or that a dangerous reaction can wait. For a concerning exposure, ask Poison Control about the specific product and symptoms. Severe symptoms or immediate danger require emergency help.^[1]

Hallucinogen Legal and Medical Status in the United States

Most psychedelic and dissociative drugs are federally controlled, although laws differ by substance and some jurisdictions have changed possession penalties or enforcement priorities. Decriminalization (removing criminal penalties for certain possession) is not the same as federal legalization, medical approval, or proof of safety. Check the specific substance and jurisdiction rather than assuming a local change applies elsewhere.^[1]

The U.S. Drug Enforcement Administration (DEA) places controlled substances into legal categories called schedules, based on accepted medical use, potential for misuse, and the likelihood of dependence. Its controlled-substances list places the six drugs compared here in three different schedules. These categories describe federal controls, not an individual’s likely response or access to treatment.^[14][15]

Schedule I means the federal classification recognizes no currently accepted U.S. medical use, a lack of accepted safety under medical supervision, and a high potential for misuse. Schedule II identifies high misuse potential that may lead to severe psychological or physical dependence. Schedule III identifies lower misuse potential than Schedules I or II, but misuse may still lead to dependence.^[14]

The U.S. Food and Drug Administration (FDA), which reviews medicines for approval, has approved the ketamine derivative esketamine for certain patients with severe depression that has not responded to other treatments. That approval does not establish the benefits or safety of nonmedical ketamine, nor does it confirm a reader’s local access or eligibility.^[1]

NIDA states that MDMA has not been FDA-approved for any medical condition. A clinical review reports that the FDA declined approval of MDMA-assisted psychotherapy in August 2024 and requested another clinical trial. “Breakthrough Therapy” designations for MDMA and two psilocybin formulations support further development and review. They are not treatment approvals.^[4][3][1]

What Hallucinogen Treatment Research Shows

Clinical research uses carefully selected participants, specified products, monitoring, and psychological support. Those conditions differ from nonmedical use. A promising result for one drug and condition does not make street products safe or establish a treatment for another condition.^[1][16]

A 2024 Cochrane systematic review, which used planned methods to find and assess studies, examined psychedelic-assisted therapy for anxiety, depression, and distress in people with life-threatening illness. It included six trials, with 149 people assigned to groups by chance and 140 analyzed.^[17] Evidence was of low or very low certainty, limiting confidence in the benefits and harms.^[17]

In an alcohol-use-disorder trial that assigned participants to groups by chance, heavy-drinking days averaged 9.7% with psilocybin and 23.6% with the active placebo over 32 weeks.^[18] The comparison used diphenhydramine, an antihistamine that produces noticeable effects, instead of psilocybin. Both groups received psychotherapy.^[18] This describes a supervised treatment study, not an instruction to self-treat with psilocybin.^[18]

Most participants correctly guessed which treatment they received, which can affect how a trial’s results are interpreted. Whether benefits lasted beyond 32 weeks was not established.^[16]

David Yaden, identified by Johns Hopkins Medicine as the Griffiths Professor of Psychedelic Research, explained that safety research involved carefully controlled settings and screened participants: “So these conclusions should not be generalized to other settings, such as recreational use.”^[19]

Esketamine has an FDA-approved role in certain depression treatment, while psilocybin is not FDA-approved. MDMA-assisted therapy did not receive FDA approval in August 2024. Different formulations, diagnoses, and regulatory decisions should not be treated as interchangeable.^[1][3][16]

Evidence for microdosing remains limited. Small amounts are not a guarantee of benefit or safety. The National Center for Complementary and Integrative Health (NCCIH) notes possible adverse effects and uncertainty about the practice.^[16]

Hallucinogen Side Effects and Drug Interactions

Short-term physical side effects can include headache, abdominal pain, nausea, vomiting, diarrhea, trembling, rapid heartbeat, or elevated blood pressure. These physical effects are typically mild or moderate but sometimes require medical care. Fear, confusion, agitation, and panic can also occur. Impaired judgment adds a separate risk of injury.^[1]

Different drugs can produce different emergencies. At moderate to high doses, PCP can cause seizures, severe muscle contractions, aggressive behavior, or psychotic symptoms. At moderate to high doses, ketamine can cause sedation, immobility, and memory loss. Severe MDMA intoxication can involve overheating, seizures, or psychiatric symptoms that threaten safety.^[2][3]

Poison-control data show what sometimes prompts help-seeking, not the likelihood of harm among all users. Among callers reporting LSD or psilocybin exposure during 2000–2016, problems included agitation, rapid heartbeat, dilated pupils, confusion, and vomiting. About 17% of LSD-related callers and 6% of psilocybin-related callers were admitted to critical care, intensive hospital monitoring and treatment.^[1] These figures cannot rank the drugs’ overall safety.^[1]

Hallucinogen Interactions with Medicines and Other Substances

Dissociative drugs can be especially dangerous when combined with high doses of alcohol or other sedating drugs that slow brain activity. NIDA warns that these combinations can cause respiratory distress or arrest (difficulty breathing or breathing that stops) and can be fatal. Trouble breathing after drug use needs immediate medical help. Call 911.^[2][1]

Combining substances can produce effects not seen with either substance alone and complicate identifying the cause of a reaction. NIDA specifically warns that MDMA used with alcohol or certain prescription medicines, including selective serotonin reuptake inhibitors, may increase negative health effects. These antidepressants, often called SSRIs, change serotonin signaling in the brain.^[4][1]

Researchers also suspect interactions between some psychedelics and other serotonin-increasing substances. Excessive serotonin activity can cause serotonin syndrome, also called serotonin toxicity. Reported cases involving psychedelics are exceedingly rare, but the condition can occasionally be life-threatening. The risk is not established equally for every drug combination.^[1]

A useful question for a clinician or pharmacist is, “Could any of my prescription medicines, nonprescription products, supplements, or other substance use conflict with this treatment?” Trial exclusions illustrate why benefits cannot be assumed to apply to every medication combination.^[1][18]

Hallucinogen Product Identity and Contamination

“Molly” is not proven safer or purer than “ecstasy.” Products sold as MDMA have contained other drugs, including ketamine, amphetamines, and synthetic cathinones, sometimes called “bath salts.” Counterfeit products and use of several substances together also complicate reports about newer psychoactive drugs. Routine hospital drug screens may not detect many of these compounds.^[3][4][13]

Fentanyl contamination of psychedelic or dissociative products is possible, but its frequency remains uncertain. Fentanyl is colorless and odorless and can cause overdose or death. Chemical testing can help identify some contaminants. It does not establish that a product or an individual’s response will be safe.^[1][3]

Who May Face Greater Hallucinogen Risks?

Individual responses cannot be predicted from a checklist. Mental and physical health, age, medications, the product, and surroundings all matter. Particular caution is warranted when clinical research has excluded people with similar health histories or when an environment makes impaired judgment especially dangerous.^[1][18]

Hallucinogens and Mental Health History

Psychedelics may trigger schizophrenia-like illness in people with predisposing factors, although evidence that they cause persistent psychiatric problems in most users is limited. PCP and ketamine can worsen symptoms in people with schizophrenia and can cause short-term psychosis. PCP-related psychosis may persist for days to weeks.^[1]

A population study in Ontario, Canada, examined more than 9.3 million insured people ages 14–65 with no baseline bipolar disorder.^[20] Among 7,285 people who required an emergency visit or hospitalization involving hallucinogens, 1.43% had emergency or hospital care for mania within three years, compared with 0.06% in an age- and sex-matched general-population comparison.^[20]

Mania is markedly elevated or irritable mood with increased energy or activity.^[20]

After adjustment for demographic and prior mental-health and substance-use care differences, hallucinogen-related acute care remained associated with a higher rate of later mania. This does not prove that hallucinogens caused it. The finding concerns a subgroup who needed hospital-based care, not everyone who uses hallucinogens, and supports taking follow-up mental health care seriously after such an event.^[20]

Hallucinogen Risks During Pregnancy and with Medical Conditions

Increased blood pressure or heart rate may be especially relevant for someone with heart or blood vessel disease. Medical conditions and medications deserve individual review. Treatment trials excluded conditions that could make study medications unsafe, so trial results are not a substitute for that assessment.^[1][18]

Pregnancy evidence is limited, but it is not uniformly absent. NIDA reports that a few studies of prenatal MDMA exposure suggest increased risks of birth defects, including heart problems, and delays in motor development such as standing and walking. These findings concern MDMA and should not be generalized into precise risk estimates for every hallucinogen. Discuss a pregnancy exposure with a healthcare professional.^[4]

The therapeutic studies described here do not establish safety during pregnancy or breastfeeding. They also do not establish safety for children, adolescents, or older adults outside the studied age ranges. Age can influence effects, but the guidance does not provide a simple ranking of risk by age. Ask what evidence applies to your age, health history, and specific exposure.^[1][17][18]

Hallucinogen Safety and the Surrounding Environment

Hazards such as traffic, heights, water, or unfamiliar surroundings can become more dangerous when perception is impaired. Being without someone able to prevent or respond to an emergency adds concern. A calm setting cannot remove a drug’s medical risks, but immediate surroundings and access to help are important safety considerations.^[1]

Hallucinogen Effects That Persist After Use

After-effects are different from ongoing intoxication. An MDMA comedown can include low mood, irritability, fatigue, anxiety, appetite changes, headache, sleep problems, and trouble concentrating or remembering. Symptoms may persist for four to seven days. Persistent or severe symptoms deserve assessment rather than an assumption that they must be harmless because they followed drug use.^[3]

Brief recurring perceptions, sometimes called flashbacks, may last seconds or minutes. Hallucinogen persisting perception disorder involves longer-lasting or recurring perceptual episodes that cause distress or interfere with life and may recur years later. Research relies substantially on self-reports, and its causes, course, prevention, and treatment remain uncertain. Seek assessment for recurring visual changes or other symptoms affecting daily life.^[1]

Unsupervised ketamine use has also been associated with memory loss, depression, anxiety, and substance-use-disorder symptoms in a review of 25 studies. These associations do not show that ketamine caused every reported problem, but they reinforce the distinction between supervised treatment and repeated nonmedical use.^[1]

Reducing Hallucinogen Harm and Responding to Distress

If use may happen, focus on preventing injury, avoiding uncertain combinations, and making help reachable. These steps reduce some risks but do not make an unregulated product safe. Drug-checking approaches may identify some contaminants, while uncertainty about strength and individual response remains.^[1][3]

Practical precautions include the following:

• Avoid driving, cycling in traffic, swimming, climbing, operating equipment, or supervising children while impaired.^[1]
• Avoid combining substances, especially when product identity or interactions are uncertain.^[1][4]
• Do not rely on a seller’s label, product appearance, or a familiar name to establish contents.^[3][13]
• Stay away from physical hazards and, where possible, have a sober, trusted person able to respond to distress or an emergency.^[1]

If someone is experiencing a bad trip, prioritize safety rather than debating what they are experiencing. Speak calmly and avoid confrontation. Help them move away from hazards if you can do so safely. Verbal de-escalation is described in clinical reports of psychoactive-drug intoxication, but it is not a substitute for emergency care when safety cannot be maintained.^[13][1]

For exposure questions or a concerning reaction in the United States, call Poison Control at 1-800-222-1222. Share what is known about the product, timing, symptoms, and other substances or medicines, including uncertainty about contents. Do not delay seeking help because the exact drug is unknown.^[1][13]

When Does a Hallucinogen Reaction Need Emergency Help?

Call 911 for severe symptoms or immediate danger. Do not assume a dangerous reaction is simply a “bad trip” or wait for an expected duration to pass.^[1]

Reasons for emergency help include:

• Trouble breathing or breathing that stops.^[2][1]
• A seizure or severe overheating.^[3]
• Severe agitation or psychosis that threatens the person’s or another person’s safety.^[3]
• Suicidal behavior, imminent risk of self-harm, or inability to maintain basic personal safety.^[3]

For emotional crisis support, including suicidal thoughts, call 988 or text 988. Immediate physical danger or severe intoxication still calls for 911.^[21][1]

Finding Hallucinogen Support That Fits Your Needs

Support can begin with a conversation about the problem you want help changing. Treatment can include counseling, support groups, and more intensive care when needed. Ask a provider about experience with the substance involved, other mental health concerns, and the level of care that fits your situation.^[7][22]

Support When You Are Unsure About Changing Hallucinogen Use

As an optional first step, note what you hoped to gain, what happened afterward, and whether use affected mood, spending, responsibilities, relationships, or safety. Bring those observations to a counselor if you want to explore them. You do not need to arrive with a complete plan.

Motivational interviewing is a counseling approach that explores mixed feelings, readiness, goals, and possible next steps. It is among the outpatient approaches used for MDMA-related problems. Ask a prospective counselor how they work with someone who is uncertain about change, what information is private, and whether involving family is optional.^[23][3]

Treatment for Cutting Back or Stopping Hallucinogen Use

A review of MDMA describes outpatient approaches including supportive psychotherapy, motivational interviewing, cognitive behavioral therapy, family therapy and group support. It also describes inpatient or short-term rehabilitation depending on the severity of MDMA-related problems. This MDMA-specific discussion does not establish how well these approaches work for other hallucinogens.^[3]

Cognitive behavioral therapy examines how thoughts, expectations, situations, and coping responses relate to substance use, focusing on current problems and attainable goals. This general treatment approach can be discussed during an individual assessment.^[24][7]

More generally, the level of substance use care should fit the person’s situation, including other medical or mental health concerns. Options may include outpatient, intensive outpatient or residential care. Discuss both substance use and ongoing symptoms during assessment rather than assuming one must be addressed before the other.^[7]

Finding Hallucinogen Treatment with Cost or Privacy Concerns

The Substance Abuse and Mental Health Services Administration (SAMHSA) National Helpline is a free, confidential information and referral service at 1-800-662-HELP (4357). It operates around the clock in English and Spanish and can connect individuals with treatment facilities, support groups, and community organizations. It provides referrals, not counseling, and does not require family involvement to call.^[22]

For people without insurance or with limited coverage, the helpline can refer to state offices responsible for state-funded treatment and often to facilities with sliding-scale fees or that accept Medicare or Medicaid. Availability and costs still need to be checked with the program. The helpline does not ask for personal information, though it may ask for your location to identify resources.^[22]

You can also text your five-digit ZIP code to 435748 for SAMHSA’s English-language treatment referral service. Message and data rates may apply. If travel or scheduling is difficult, ask programs whether phone or video care is offered. Confirm availability, privacy arrangements, costs, and experience with your specific concern.^[22]

Explore Specific Hallucinogen Questions

Choose the guide that matches the substance or experience you want to understand. These topics have different risks and evidence, so a reassuring finding about one does not answer every question.

• Psilocybin: mushroom effects and research context.
• LSD: effects and use-related concerns.
• DMT and ayahuasca: different preparations and experiences.
• Microdosing: small-dose claims and their limitations.
• Bad trips: distress during an experience. Severe symptoms or immediate danger require emergency help.
• HPPD: persistent or recurring perception changes that deserve assessment.
• Ketamine and MDMA/ecstasy: distinct drug profiles, dependence concerns and treatment questions.

Choosing a Next Step for Hallucinogen Help

If you are learning about hallucinogens, identify the specific drug rather than treating the group as interchangeable. If you are considering supervised treatment, ask what evidence applies to your condition, which formulation is proposed, how health and medication risks are assessed, and what follow-up is included. Trial findings depend on these distinctions.^[1][17][18]

If you have lingering symptoms, seek a medical or mental health assessment. If use is affecting daily life (or you simply want to understand your options) consider one conversation with a counselor or SAMHSA’s helpline. For an immediate exposure concern, use Poison Control. For severe illness or immediate danger, call 911. You can choose the next step that fits the situation without deciding everything today.^[3][22][1]

For emotional crisis support in the United States, call 988, text 988 or chat with the 988 Lifeline. Call 911 for severe intoxication or immediate danger.^[21][1]